VST Bio Corporation
Biotechnology company developing intravenously delivered monoclonal antibody therapeutics that selectively regulate vascular permeability to limit edema and tissue damage in acute ischemic stroke and other injury- or inflammation-driven conditions. The company translates a university-discovered molecular pathway into human and humanized antibodies, has completed preclinical efficacy and safety studies in rodents and non-human primates, holds a patent family covering the mechanism and compositions, and is pursuing regulatory filings and clinical development.
Industries
N/A
Nr. of Employees
small (1-50)
Products
IV-formulated humanized monoclonal antibody to normalize vascular permeability
An intravenous monoclonal antibody therapy designed to selectively block injury- and inflammation-induced vascular leakage, reduce edema and limit expansion of tissue damage after acute ischemic stroke; developed for administration up to several days after symptom onset.
VB-001
A proprietary humanized antibody designed to revert vascular dysfunction, normalize vascular leakage, and prevent ongoing cerebral damage in ischemic stroke patients.
Anti-Sdc2 Ab
An anti-syndecan-2 monoclonal antibody therapy that selectively inhibits VEGF-induced vascular permeability, reducing edema and inflammation in acute stroke, myocardial infarction, and other disease models.
VST Bio Humanized Antibody
A humanized antibody therapy delivered via simple IV bolus infusion that reverses vascular dysfunction, controls injury-induced inflammation, and reduces cerebral damage in acute stroke and cardiovascular disease.
IV-formulated humanized monoclonal antibody to normalize vascular permeability
An intravenous monoclonal antibody therapy designed to selectively block injury- and inflammation-induced vascular leakage, reduce edema and limit expansion of tissue damage after acute ischemic stroke; developed for administration up to several days after symptom onset.
VB-001
A proprietary humanized antibody designed to revert vascular dysfunction, normalize vascular leakage, and prevent ongoing cerebral damage in ischemic stroke patients.
Anti-Sdc2 Ab
An anti-syndecan-2 monoclonal antibody therapy that selectively inhibits VEGF-induced vascular permeability, reducing edema and inflammation in acute stroke, myocardial infarction, and other disease models.
VST Bio Humanized Antibody
A humanized antibody therapy delivered via simple IV bolus infusion that reverses vascular dysfunction, controls injury-induced inflammation, and reduces cerebral damage in acute stroke and cardiovascular disease.
Services
Academic and industry partnering for translation of vascular permeability biology into therapeutic antibodies.
Academic and industry partnering for translation of vascular permeability biology into therapeutic antibodies.
Expertise Areas
- Therapeutic monoclonal antibody development
- Vascular biology and regulation of permeability
- Preclinical stroke modeling (rodent and NHP)
- CMC and IV formulation for biologics
Key Technologies
- Monoclonal antibody discovery and humanization
- IV formulation for parenteral antibody administration
- Modulation of VEGFR2 phosphorylation via syndecan/DEP1 pathway
- Rodent and non-human primate ischemic stroke models
News & Updates
Presentation of non-clinical study results showing effects of anti-syndecan-2 antibody therapy in preclinical stroke models.
Publication reporting the mechanism and therapeutic data related to regulation of vascular permeability and antibody effects in stroke models.
Awarded $4.5M by a philanthropic fund to support development of an intravenous antibody therapy for reducing cerebral damage in acute ischemic stroke.
Single IV bolus dosing in non-human primate stroke models reduced cerebral damage by ~50-80% and was reported as well tolerated; rodent studies showed reductions in VEGF-induced leakage and reduced cerebral damage (up to ~40%).
Presentation of non-clinical study results showing effects of anti-syndecan-2 antibody therapy in preclinical stroke models.
Publication reporting the mechanism and therapeutic data related to regulation of vascular permeability and antibody effects in stroke models.
Awarded $4.5M by a philanthropic fund to support development of an intravenous antibody therapy for reducing cerebral damage in acute ischemic stroke.
Single IV bolus dosing in non-human primate stroke models reduced cerebral damage by ~50-80% and was reported as well tolerated; rodent studies showed reductions in VEGF-induced leakage and reduced cerebral damage (up to ~40%).